Jane Street Group LLC Has $350,000 Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Jane Street Group LLC cut its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 63.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 164,523 shares of the company's stock after selling 286,198 shares during the quarter. Jane Street Group LLC owned 0.08% of Allogene Therapeutics worth $350,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALLO. Cibc World Markets Corp acquired a new position in shares of Allogene Therapeutics in the 4th quarter valued at approximately $26,000. PAX Financial Group LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $27,000. RPO LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $31,000. Syon Capital LLC acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $39,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $43,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Price Performance

Shares of NASDAQ:ALLO remained flat at $1.29 during mid-day trading on Thursday. 1,646,951 shares of the stock were exchanged, compared to its average volume of 3,311,131. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $3.78. The firm's fifty day simple moving average is $1.34 and its two-hundred day simple moving average is $1.76. The firm has a market cap of $282.16 million, a price-to-earnings ratio of -0.83 and a beta of 0.60.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). Sell-side analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ALLO shares. Truist Financial cut their target price on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Oppenheimer cut their target price on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. Citigroup cut their target price on shares of Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research report on Wednesday, May 14th. Finally, HC Wainwright cut their target price on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.44.

Insiders Place Their Bets

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now directly owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 61,757 shares of company stock worth $115,873. 13.20% of the stock is currently owned by company insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).